Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 8/20 | 0.66 |
| ▸ | CCNE2 | O96020 | 11/20 | 0.57 |
| ▸ | CCNE1 | P24864 | 11/20 | 0.57 |
| ▸ | CDK2 | P24941 | 11/20 | 0.57 |
| ▸ | CDK4 | P11802 | 5/20 | 0.57 |
| ▸ | CCND1 | P24385 | 5/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21802969 | 0.83 | EGLN1 (0.64) | EGLN1MAPTMAPK1HTTNPSR1 | |
| SCHEMBL627030 | 0.83 | EGLN1 (0.66) | EGLN1CCNE2CCNE1CDK2CDK4 | |
| SCHEMBL16626248 | 0.81 | EGLN1 (0.66) | EGLN1MAPTMAPK1HTTNPSR1 | |
| SCHEMBL16626157 | 0.81 | EGLN1 (0.66) | EGLN1MAPTMAPK1HTTNPSR1 | |
| SCHEMBL622236 | 0.79 | EGLN1 (1.00) | EGLN1 | |
| SCHEMBL627750 | 0.79 | EGLN1 (0.67) | EGLN1MAPTMAPK1HTTNPSR1 | |
| SCHEMBL628318 | 0.78 | EGLN1 (0.66) | EGLN1 | |
| SCHEMBL628188 | 0.78 | EGLN1 (0.67) | EGLN1 | |
| SCHEMBL16626187 | 0.77 | EGLN1 (0.64) | EGLN1MAPTMAPK1HTTNPSR1 | |
| SCHEMBL627205 | 0.76 | EGLN1 (0.69) | EGLN1MAPTMAPK1HTTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975062-B2 | 4-aminoquinazolinyl compounds as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV | 2021-04-13 | — | — | US | disclosed |
| US-20200095234-A1 | 4-AMINOQUINAZOLINYL COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-03-26 | — | — | US | disclosed |
| US-9006251-B2 | 4-aminoquinazolin-2-yl-1-pyrrazole-4-carboxylic acid compounds as prolyl hydroxylase inhibitors | JANSSEN PHARAMCEUTICA NV (BE) | 2015-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975062-B2 | 4-aminoquinazolinyl compounds as prolyl hydroxylase inhibitors | P4HA1, EGLN3, EGLN2 | EGLN1 6/4885CCNE2 1319/4885CCNE1 1522/4885 |
| US-20200095234-A1 | 4-AMINOQUINAZOLINYL COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, EGLN3, EGLN2 | EGLN1 6/4885CCNE2 1319/4885CCNE1 1522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.